✦ LIBER ✦

848 VIRAL KINETICS DURING TREATMENT WITH A CONTROLLED-RELEASE RECOMBINANT INTERFERON ALFA 2B IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS

✍ Scribed by E. Herrmann; S. Zeuzem; I. Dzyublyk; L. Moroz; I. Zaytsev; S. Martens; E.J. van Hoogdalem; J.E. Humphries

Book ID: 117376774
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 57 KB
Volume: 48
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(08)60850-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

818 VIRAL KINETICS AND PHARMACODYNAMICS

818 VIRAL KINETICS AND PHARMACODYNAMICS OF ALBINTERFERON ALFA-2B IN INTERFERON TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C

✍ A.U. Neumann; L. Rozenberg; V.G. Bain; J.G. McHutchison; E. Pulkstenis; G.M. Sub 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

942 VIRAL KINETIC MODELING DURING TREATM

942 VIRAL KINETIC MODELING DURING TREATMENT WITH INTERFERON LAMBDA-1A IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS

✍ M.G. Dodds; D.F. Hausman; D.M. Miller 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Viral kinetics in genotype 1 chronic hep

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

✍ Maria Buti; Francisco Sanchez-Avila; Yoav Lurie; Carlos Stalgis; Auristela Valdé 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

Controlled release recombinant human int

Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial

✍ I. Dzyublyk; T. Yegorova; L. Moroz; O. Popovych; I. Zaytsev; V. Miroshnichenko; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB

Peginterferon alfa-2b plus ribavirin for

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

✍ Savino Bruno; Calogero Cammà; Vito Di Marco; Mariagrazia Rumi; Maria Vinci; Mari 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 373 KB

Albinterferon alfa-2b dosed every two or

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C

✍ Stefan Zeuzem; Eric M. Yoshida; Yves Benhamou; Stephen Pianko; Vincent G. Bain; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 528 KB

The efficacy and safety of albinterferon alfa-2b (alb-IFN), a novel recombinant protein consisting of interferon alfa-2b genetically fused to human albumin, was evaluated in a phase 2b, open-label study of patients with genotype 1, chronic hepatitis C. In all, 458 IFN-alfa treatment-naı ¨ve patients